Tuesday September 22, 2015 0 comments
FORT COLLINS -- KromaTiD announced it received its third U.S. patent to expand its full genome screening platform to include a new set of unique methods for understanding the structure of novel disease-causing mutations.
Based on its proprietary chromatid-specific imaging platform, KromaTiD said its dGH assay is the only imaging technology capable of determining DNA sequence, location and orientation in a single test.
With these new capabilities, KromaTiD said it is now able to estimate the size of DNA rearrangements in the same assay.
“Our customers are developing precision medicines and interventions for diseases such as cancers and developmental disorders,” said Chris Tompkins, KromaTiD president and COO.
“With dGH’s new capability, we can provide them with a deeper understanding of disease genetics during early screening and discovery studies, speeding results and making a meaningful impact on their programs.”
KromaTiD said its commercial offering includes kits and assays for detecting known DNA rearrangements and for discovering disease-causing rearrangements, custom assays for tracking rearrangements to genes and for validating results from sequencing and arrays.